Table 1.

Biologic agents used in adult rheumatologic autoimmune diseases

Agent	Type	Mechanism of Action	Studied in	FDA approval
Rituximab	Anti-CD20 mAb	B cell depletion	RA, CV, SLE	RA
Abatacept	CTLA4 Ig	Costimulation inhibitor	RA	RA
Tocilizumab	Anti IL-6R	IL-6 inhibition	RA	None
Etanercept	TNF-α R/Fc fusion protein	TNF inhibition	RA, AS, PsA DM/PM, SA, WG (negative results)	RA, AS, PsA
Adalimumab	Anti-TNF-α mAb	TNF inhibition	RA, AS, PsA	RA, AS, PsA
Infliximab	Anti TNF-α mAb	TNF inhibition	RA, AS, PsA DM/PM, SA, GCA (negative results) PMR	RA, AS, PsA
Anakinra	IL-1ra	IL-1 inhibition	RA, AS,	RA